Thermo Fisher Scientific: Investor Day recap: Don’t lose the faith!

Research evidence excerpt

Thermo Fisher Scientific: Investor Day recap: Don’t lose the faith!

d by continued ~2-3% of share gains. Importantly, management indicated that Date Established 23-Apr-2026

an increasing portion of the progression is supported by specific trends already Investment Opinion B-1-7

emerging. Supporting drivers include improving Pharma/Biotech trends (orders > 52-Week Range 385.46 USD - 643.99 USD

revenues), with stronger Biotech funding increasingly translating into clinical activity, Mrkt Val (mn) / Shares Out (mn) 175,516 USD / 388.5

alongside incremental Pharma Services capacity coming online (reshoring) that has Free Float 99.9%

already been contracted. Management also spoke at length about demand from Average Daily Value (mn) 1036.21 USD

semiconductor markets as they look to meet growing AI needs of their customers. BofA Ticker / Exchange TMO / NYS

Bloomberg / Reuters TMO US / TMO.N

AI increasingly hailed as tailwind / positive ROE (2026E) 17.9%

AI was a central topic throughout the day, with management reiterating its view that AI Net Dbt to Eqty (Dec-2025A) 58.6%

should serve as a tailwind for the broader life sciences ecosystem through improved

R&D productivity and greater predictability in drug development. The discussion

AI: Artificial intelligenceincreasingly shifted beyond internal efficiency benefits toward areas where AI may drive

incremental demand, including greater wet-lab validation needs, creation of large EM: Electron microscopy

biological datasets to train models, and faster clinical development timelines.

Management also highlighted early applications across clinical research and autonomous LT: Long-term

laboratory capabilities, while emphasizing that TMO’s differentiated data assets,